Felipe A. Calvo Manuel (June 2022) Chair Professor & Chairman. Department of Radiation Oncology. Director Proton Therapy Center. Clínica Universidad de Navarra. Universidad de Navarra. Madrid-Pamplona, Spain Education Medical Degree: Autonoma University of Madrid, Spain (1978). Radiation Oncology specialty 1983 (Residency. University Hospital Puerta de Hierro, Madrid, Spain). Postgraduate Fellow: The Royal Marsden Hospital (London, England); Hahnemann University Hospital/Children´s Hospital of Philadelphia. 1983-84. (Philadelphia, USA). PhD Degree. University of Navarra (Pamplona. Spain). 1986. Health Care Responsibilities Director (1985) Radiation Oncology Department. Clinica Universidad de Navarra (Pamplona, Spain). Attending physician (1991-93). Radiation Oncology and Nuclear Medicine. Hahnemann University (Philadelphia, USA). Professor and Chairman (1993-2017). Department of Oncology. General University Hospital Gregorio Marañon. Madrid, Spain. Professor and Chairman Department of Oncology, Medical Director Proton Therapy Center (2018- ). Clinica Universidad de Navarra. Madrid. Spain Teaching (4 ANECA credits, Agency for National Accreditation in Education) Associate Clinical Professor 1985. Associate Professor 1987. University of Navarra. Full Professor: Radiation Oncology. Hahnemann University. 1991-93. Associate Professor (1993) Radiology and Medical Physics. Complutense University (Madrid, Spain); Full Professor (1995); Chair Professor (2007-2017). Hospital Vice-Dean 2006-10 Faculty of Medicine (Complutense University) at the General University Hospital Gregorio Marañon. Chair Professor University of Navarra (2018-) Coordinator, Research and Education Unit. Clinica Universidad de Navarra. Madrid. Research (6 CNEAI credits, Agency for National Research Accreditation) Director 26 PhD thesis. Associate Researcher 8 competitive grants. Principal Investigator 5 competitive grants. Chief (2011-2017) of consolidated Research Group on “Interdisciplinary Biotechnological Oncology” (Institute of Sanitary Research Gregorio Marañon, Madrid, Spain). Coordinator (2018- ) registered research group “INTRA Interdiciplinar Teragnosis and Radiosomics” Universidad de Navarra (Spain). Publications (last 10 years): 5 books (11 co-editor), 38 chapters, 157 journal articles, 265 abstracts. Cumulative impact factor > 300; (>50% Q1). Professional Vice- President 1984-86 Spanish Society of Radiation Oncology / President 1986-92 National Commission of Radiation Oncology (Minister of Health) / President 1998 International Society of Intraoperative Radiotherapy /Patroon (2002-10) Scientific Foundation. Spanish Association Against Cancer / Educational Council (2010-) European Society for Therapeutic Radiology and Oncology / Scientific Board member (2012- ) European School of Oncology. Member Spanish Royal Academy of Medicine.

I am a PhD candidate at the GSI Helmholtz Centre for Heavy Ion Research and the Max Planck Institute for Nuclear Physics. The purpose of my project is to follow the fate of the harmful reactive species produced in a biological environment by radiolysis from different radiation qualities, in order to establish a connection between their initial yields and the early biological response. To this aim, an extension of the Monte Carlo track structure code TRAX-CHEM into the "homogeneous” biochemical stage of radiation damage (up to roughly s) is in progress.

Pierluigi Casolaro received the PhD in Physics in 2019 from the University of Naples Federico II. He worked at INFN as PI of a project on beam monitoring for radiation hardness assurance. He currently works as a Postdoc at the University of Bern where he is PI of a project on the development of new detectors for FLASH radiation therapy.

Dr. Chakravarti is Professor and Chair of the Department of Radiation Oncology at The Ohio State University, where he holds the Klotz Chair in Cancer Research and directs the Brain Tumor Program. He was named to the Castle Connolly list of “America's Top Doctors” from 2012-2019 and is a member of the Translational Therapeutics Program at the OSUCCC -James. His focus is FLASH research as well as translational cancer research to identify novel biomarkers that are predictive of treatment efficacy and survival, and to uncover molecular and genetic mechanisms of treatment resistance to advance care of cancer patients.

Medical Physics Program and Innovation Fellow at Thayer School of Engineering at Dartmouth College

Professor Combs is a leading expert in the field of radiation oncology and radiation therapy. Her key expertise is highly conformal radiation therapy (stereotactic treatment, IMRT/IGRT/ART, protons and carbon ions). Her scientific work includes areas including treatment optimization for brain and skull base tumors, biomarkers in radiation oncology, pediatric oncology, gastrointestinal oncology, uro-oncology, gynecological oncology, radiochemotherapy and radioimmunotherapy. Prof. Combs studied medicine in Heidelberg, and in Norfolk and San Antonio, USA. After her graduation and promotion 2003, she worked as research associate in Heidelberg. Following her postdoctoral lecture qualification 2009, she was promoted in 2011 to vice chair of the radiation oncology department in Heidelberg. 2014, Prof. Combs was appointed professor and chair of the TUM department of radiation oncology. In 2015, she also took over the institute of radiation medicine of the Helmholtz Zentrum. Since 2019, Prof. Combs heads the TUM senate.

Rob Coppes did a PhD in Molecular Pharmacology and a post-doc in radiobiology. He became a full professor of Radiotherapy with focus on the radiation biology of normal tissues in 2012. In 2015 he received the Bacq-and-Alexander Award of the European Radiation Research Society to an outstanding European researcher to recognize achievements in the field of radiation research. He serve(s)(d) as editor or scientific board member of several international journals, societies and institutes. He has a strong background in cell biology and radiation biology with specific training in clinical radiation biology. He has experience in clinical radiobiology related oncology and has led multiple EU and Dutch research consortia and other research projects and extensively participates in training and teaching in radiobiology. His research focused on the response of normal tissues to radiation. His lab showed novel mechanisms and developed novel tools to investigate normal tissue responses and showed regional differences in normal tissues such as spinal cord, lungs and salivary gland, challenging the existing concepts and models and rethinking the best ways to plan patients for radiotherapy. In the salivary gland a completely different mechanism responsible for the regional differences in radiosensitivity of the tissue was found. It was shown that the tissues stem cells are not equally divided over the tissue and found a high accumulation of these cells in a specific area of the gland. A relation was found between the sensitive area and the stem cell response using novel by his group developed techniques. His lab was the first lab to develop methods of using tissue and tumour derived organoids to study the response of stem cells to different types of radiation. A first clinical trial using salivary gland stem cell transplantation is ongoing. Currently, attempts are made to investigate the FLASH effect using tumor and normal tissue stem cell derived organoids.